Skip to main content
SpringerLink
Log in

Prognostic Value of Tumor-to-Blood Standardized Uptake Ratio in Patients with Resectable Non-Small-Cell Lung Cancer

  • Original Article
  • Published:
Nuclear Medicine and Molecular Imaging Aims and scope Submit manuscript

Abstract

Objectives

Previously published studies showed that the standard tumor-to-blood standardized uptake value (SUV) ratio (SUR) was a more accurate prognostic method than tumor maximum standardized uptake value (SUVmax). This study evaluated and compared prognostic value of positron emission tomography (PET) parameters and normalized value of PET parameters by blood pool SUV in non-small-cell lung cancer (NSCLC) patients who received curative surgery.

Methods

Seventy-seven patients who underwent curative resection for NSCLC between January 2010 to December 2013 were enrolled in this study. 18Fluorine-fluorodeoxyglucose (18F-FDG) positron emission tomography/computed tomography (PET/CT) was performed before surgery. The mean standardized uptake value (SUVmean), SUVmax, metabolic tumor volume (MTV), and total lesion glycolysis (TLG) of each lesion was measured, on the workstation. SURmean, SURmax, and TLGSUR were calculated by dividing each of them by descending aorta SUVmean. Cox proportional hazards regression was used to analyze the effect of age, sex, pathological parameters, and PET parameters on recurrence and death.

Results

In Cox regression analysis, N stage predicted for both recurrence (p < 0.0001) and death (p < 0.0001). SURmax predicted recurrence (p = 0.0014), not death. Area under the receiver operating characteristic curve of SURmax was 0.759 with cutoff value 4.004. However, SUVmax, SUVmean, MTV, TLG, SURmean, and TLGSUR predicted neither recurrence nor death.

Conclusions

Among PET parameters, SURmax was the independent predictor of recurrence in NSCLC patients who received curative surgery. N stage was the independent prognostic factor for both recurrence and death. Both parameters could be used to stratify the risk of NSCLC patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Jung K-W, Park S, Kong H-J, Won Y-J, Lee JY, Seo HG, et al. Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2009. Cancer Res Treat. 2012;44:11–24.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Bareschino MA, Schettino C, Rossi A, Maione P, Sacco PC, Zeppa R, et al. Treatment of advanced non small cell lung cancer. J Thorac Dis. 2011;3:122–33.

    PubMed  PubMed Central  Google Scholar 

  3. Crino L, Weder W, van Meerbeeck J, Felip E, Group EGW. Early stage and locally advanced (non-metastatic) non-small-cell lung cancer: esmo clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol: Off J Eur Soc Med Oncol / ESMO. 2010;21 Suppl 5:v103–15.

    Article  Google Scholar 

  4. Bunyaviroch T, Coleman RE. Pet evaluation of lung cancer. J Nucl Med. 2006;47:451–69.

    PubMed  Google Scholar 

  5. Adams MC, Turkington TG, Wilson JM, Wong TZ. A systematic review of the factors affecting accuracy of suv measurements. AJR Am J Roentgenol. 2010;195:310–20.

    Article  PubMed  Google Scholar 

  6. Zhu D, Ma T, Niu Z, Zheng J, Han A, Zhao S, et al. Prognostic significance of metabolic parameters measured by (18)f-fluorodeoxyglucose positron emission tomography/computed tomography in patients with small cell lung cancer. Lung Cancer. 2011;73:332–7.

    Article  PubMed  Google Scholar 

  7. Kim K, Kim SJ, Kim IJ, Kim YS, Pak K, Kim H. Prognostic value of volumetric parameters measured by f-18 fdg pet/ct in surgically resected non-small-cell lung cancer. Nucl Med Commun. 2012;33:613–20.

    Article  PubMed  Google Scholar 

  8. Im HJ, Pak K, Cheon GJ, Kang KW, Kim SJ, Kim IJ, et al. Prognostic value of volumetric parameters of (18)f-fdg pet in non-small-cell lung cancer: a meta-analysis. Eur J Nucl Med Mol Imaging. 2015;42:241–51.

  9. Kim DH, Son SH, Kim CY, Hong CM, Oh JR, Song BI, et al. Prediction for recurrence using f-18 fdg pet/ct in pathologic n0 lung adenocarcinoma after curative surgery. Ann Surg Oncol. 2014;21:589–96.

    Article  PubMed  Google Scholar 

  10. van den Hoff J, Oehme L, Schramm G, Maus J, Lougovski A, Petr J, et al. The pet-derived tumor-to-blood standard uptake ratio (sur) is superior to tumor suv as a surrogate parameter of the metabolic rate of fdg. EJNMMI Res. 2013;3:77.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Butof R, Hofheinz F, Zophel K, Stadelmann T, Schmollack J, Jentsch C, et al. Prognostic value of pretherapeutic tumor-to-blood standardized uptake ratio in patients with esophageal carcinoma. J Nucl Med. 2015;56:1150–6.

    Article  CAS  PubMed  Google Scholar 

  12. Tas F, Ciftci R, Kilic L, Karabulut S. Age is a prognostic factor affecting survival in lung cancer patients. Oncol Lett. 2013;6:1507–13.

    CAS  PubMed  PubMed Central  Google Scholar 

  13. Asmis TR, Ding K, Seymour L, Shepherd FA, Leighl NB, Winton TL, et al. National Cancer Institute of Canada Clinical Trials G: age and comorbidity as independent prognostic factors in the treatment of non small-cell lung cancer: a review of national cancer institute of Canada clinical trials group trials. J Clin Oncol: Off J Am Soc Clin Oncol. 2008;26:54–9.

    Article  CAS  Google Scholar 

  14. Ye T, Pan Y, Wang R, Hu H, Zhang Y, Li H, et al. Analysis of the molecular and clinicopathologic features of surgically resected lung adenocarcinoma in patients under 40 years old. J Thorac Dis. 2014;6:1396–402.

    PubMed  PubMed Central  Google Scholar 

  15. Hsu CL, Chen JH, Chen KY, Shih JY, Yang JC, Yu CJ, et al. Advanced non-small cell lung cancer in the elderly: the impact of age and comorbidities on treatment modalities and patient prognosis. J Geriatr Oncol. 2015;6:38–45.

    Article  PubMed  Google Scholar 

  16. Goldstraw P, Crowley J, Chansky K, Giroux DJ, Groome PA, Rami-Porta R, et al. The iaslc lung cancer staging project: proposals for the revision of the tnm stage groupings in the forthcoming (seventh) edition of the tnm classification of malignant tumours. J Thorac Oncol: Off Publ Int Assoc Study of Lung Cancer. 2007;2:706–14.

    Article  Google Scholar 

  17. Berghmans T, Dusart M, Paesmans M, Hossein-Foucher C, Buvat I, Castaigne C, et al. Primary tumor standardized uptake value (suvmax) measured on fluorodeoxyglucose positron emission tomography (fdg-pet) is of prognostic value for survival in non-small cell lung cancer (nsclc): a systematic review and meta-analysis (ma) by the European lung cancer working party for the iaslc lung cancer staging project. J Thorac Oncol. 2008;3:6–12.

    Article  PubMed  Google Scholar 

  18. Chen HH, Chiu N-T, Su W-C, Guo H-R, Lee B-F. Prognostic value of whole-body total lesion glycolysis at pretreatment fdg pet/ct in non–small cell lung cancer. Radiology. 2012;264:559–66.

    Article  PubMed  Google Scholar 

  19. Wahl RL, Jacene H, Kasamon Y, Lodge MA. From recist to percist: evolving considerations for pet response criteria in solid tumors. J Nucl Med. 2009;50 Suppl 1:122S–50S.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Chu KP, Murphy JD, La TH, Krakow TE, Iagaru A, Graves EE, et al. Prognostic value of metabolic tumor volume and velocity in predicting head-and-neck cancer outcomes. Int J Radiat Oncol Biol Phys. 2012;83:1521–7.

    Article  PubMed  PubMed Central  Google Scholar 

  21. Takahashi Y, Oriuchi N, Otake H, Endo K, Murase K. Variability of lesion detectability and standardized uptake value according to the acquisition procedure and reconstruction among five pet scanners. Ann Nucl Med. 2008;22:543–8.

    Article  PubMed  Google Scholar 

  22. Laffon E, Adhoute X, de Clermont H, Marthan R. Is liver suv stable over time in (1)(8)f-fdg pet imaging? J Nucl Med Technol. 2011;39:258–63.

    Article  PubMed  Google Scholar 

  23. Park J, Chang KJ, Seo YS, Byun BH, Choi JH, Moon H, et al. Tumor suvmax normalized to liver uptake on (18)f-fdg pet/ct predicts the pathologic complete response after neoadjuvant chemoradiotherapy in locally advanced rectal cancer. Nucl Med Mol Imaging. 2014;48:295–302.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Song MJ, Bae SH, Lee SW, Song do S, Kim HY, Yoo Ie R, et al. 18f-fluorodeoxyglucose pet/ct predicts tumour progression after transarterial chemoembolization in hepatocellular carcinoma. Eur J Nucl Med Mol Imaging. 2013;40:865–73.

    Article  CAS  PubMed  Google Scholar 

  25. Shiono S, Abiko M, Okazaki T, Chiba M, Yabuki H, Sato T. Positron emission tomography for predicting recurrence in stage i lung adenocarcinoma: Standardized uptake value corrected by mean liver standardized uptake value. Eur J Cardiothorac Surg: Off J Eur Assoc Cardiothorac Surg. 2011;40:1165–9.

    Google Scholar 

  26. Besson FL, de Boysson H, Parienti JJ, Bouvard G, Bienvenu B, Agostini D. Towards an optimal semiquantitative approach in giant cell arteritis: An (18)f-fdg pet/ct case–control study. Eur J Nucl Med Mol Imaging. 2014;41:155–66.

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

The manuscript has not been published before or is not under consideration for publication anywhere else and has been approved by all co-authors.

Author information

Authors and Affiliations

  1. Department of Nuclear Medicine and Biomedical Research Institute, Pusan National University Hospital, Busan, Korea

    Seunghyeon Shin, Kyoungjune Pak & In Joo Kim

  2. Department of Nuclear Medicine and Research Institute for Convergence of Biomedical Science and Technology, Pusan National University Yangsan Hospital, Yangsan, Korea

    Bum Soo Kim & Seong Jang Kim

Authors
  1. Seunghyeon Shin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kyoungjune Pak
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. In Joo Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Bum Soo Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Seong Jang Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Seong Jang Kim.

Ethics declarations

Conflict of Interest

Seunghyeon Shin, Seong-Jang Kim, In Joo Kim, Kyoungjune Pak and Bum Soo Kim declare that they have no conflict of interest.

Ethical Statement

The study was approved by an institutional review board or equivalent and has been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments. All subjects in the study gave written informed consent or the institutional review board waived the need to obtain informed consent.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Shin, S., Pak, K., Kim, I.J. et al. Prognostic Value of Tumor-to-Blood Standardized Uptake Ratio in Patients with Resectable Non-Small-Cell Lung Cancer. Nucl Med Mol Imaging 51, 233–239 (2017). https://doi.org/10.1007/s13139-016-0456-3

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13139-016-0456-3

Keywords

Search

Navigation